Literature DB >> 8625515

Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice.

M B Hogarth1, P J Norsworthy, P J Allen, P K Trinder, M Loos, B J Morley, M J Walport, K A Davies.   

Abstract

We have developed an ELISA to measure murine autoantibodies to the collagenous region (CLR) of C1q, using the whole human C1q molecule as the solid-phase ligand, in the presence of 1 M NaCl. The assay was validated by testing positive sera from 20 mice using purified mouse C1q, and from 10 mice using purified human C1q-CLR, as the solid-phase ligands. There were highly significant correlations between results obtained with human C1q (whole molecule) and: (i) mouse C1q (rsp = 0.73, P less than 0.001), and (ii) human Clq-CLR alone (rsp = 0.86, P = 0.001). Antibodies to Clq were measured in 53 MRL/lpr, 17 BXSB and 25 NZB/W lupus-prone mice. Median (range) anti-C1q (CLR) antibody levels in MRL/lpr, BXSB, and NZB/W autoimmune mice aged 3 months were 22 (16-66), 21 (17-39) and 19 (15-27) EU, respectively. The median anti-Clq antibody level in MRL/lpr mice aged 5 months was 76 (35-142) EU, significantly higher than that at 3 months (U = 558, P less than 0.0005). Median anti-C1q antibody level in NZB/W mice at 8 months was 37 (13-74) EU and in BXSB mice at 11 months was 62 (31-231) EU, significantly higher than corresponding values at 3 months (U = 326, and U = 4, P less than 0.001, respectively). This is the first demonstration of anti-C1q (CLR) antibodies in NZB/W and BXSB mice. The pathologic significance and the potential utility of these antibodies for monitoring disease in lupus-prone mice are under evaluation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625515      PMCID: PMC2200417          DOI: 10.1046/j.1365-2249.1996.19725.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  6 in total

1.  Anti-C1q autoantibodies in murine lupus nephritis.

Authors:  L A Trouw; M A Seelen; R Visseren; J M G J Duijs; H Benediktsson; E de Heer; A Roos; C van Kooten; M R Daha
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

2.  Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Authors:  Leendert A Trouw; Tom W L Groeneveld; Marc A Seelen; Jacques M G J Duijs; Ingeborg M Bajema; Frans A Prins; Uday Kishore; David J Salant; J Sjef Verbeek; Cees van Kooten; Mohamed R Daha
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

3.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

Review 4.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09

5.  Deficiencies of GM-CSF and interferon gamma link inflammation and cancer.

Authors:  Thomas Enzler; Silke Gillessen; John P Manis; David Ferguson; James Fleming; Frederick W Alt; Martin Mihm; Glenn Dranoff
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

6.  Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site.

Authors:  Kinga Csorba; Lucia A Schirmbeck; Eylul Tuncer; Camillo Ribi; Pascale Roux-Lombard; Carlo Chizzolini; Uyen Huynh-Do; Dominique Vanhecke; Marten Trendelenburg
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.